Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–178.
   PubMed Web of Science ®Google Scholar
• Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–624.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–1138.
   PubMed Web of Science ®Google Scholar
• Chapple C. Pathophysiology of the lower urinary tract and CNS. Can Urol Assoc J. 2011;5(5 Suppl 2):S126–127.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005;95(3):335–340.
   PubMed Web of Science ®Google Scholar
• Sellers DJ, Chess-Williams R. Muscarinic agonists and antagonists: effects on the urinary bladder. Handb Exp Pharmacol. 2012;208:375–400.
   PubMedGoogle Scholar
• Finney SM, Andersson KE, Gillespie JI, et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503–507.
   PubMed Web of Science ®Google Scholar
• Sigala S, Mirabella G, Peroni A, et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology. 2002;60(4):719–725.
   PubMed Web of Science ®Google Scholar
• Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2013;6:1–16.
   PubMedGoogle Scholar
• Cetinel B, Onal B. Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol. 2013;54(12):806–815.
   PubMedGoogle Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–1282.
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–585.
   PubMed Web of Science ®Google Scholar
• Gomes T, Juurlink DN, Mamdani MM. Comparative adherence to oxybutynin or tolterodine among older patients. Eur J Clin Pharmacol. 2012;68(1):97–99.
   PubMed Web of Science ®Google Scholar
• Linnér L, Schioler H, Samuelsson E, et al. Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol. 2011;67(5):535–536.
   PubMed Web of Science ®Google Scholar
• Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian prescription database. Acta Obstet Gynecol Scand. 2013;92(10):1208–1215.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Rejas J, Navarro-Artieda R, et al. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J. 2014;25(4):485–492.
   PubMed Web of Science ®Google Scholar
• Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003–1008.
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–1774.
   PubMed Web of Science ®Google Scholar
• Wagg A, Diles D, Berner T. Treatment patterns for patients on overactive bladder therapy: a retrospective statistical analysis using Canadian claims data. J Health Econ Outcomes Res. 2015;3(1):43–55.
   Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562.
   PubMed Web of Science ®Google Scholar
• Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–779.
   PubMed Web of Science ®Google Scholar
• Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649–653.
   PubMed Web of Science ®Google Scholar
• Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88–119.
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4–6):473–481.
   PubMed Web of Science ®Google Scholar
• Michel MC, Korstanje C. beta3-adrenoceptor agonists for overactive bladder syndrome: role of translational pharmacology in a repositioning clinical drug development project. Pharmacol Ther. 2016;159:66–82.
   PubMed Web of Science ®Google Scholar
• Wuest M, Eichhorn B, Grimm MO, et al. Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther. 2009;328(1):213–222.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol. 2009;1(2):71–83.
   PubMedGoogle Scholar
• Leon LA, Hoffman BE, Gardner SD, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole −2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2008;326(1):178–185.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V. Mirabegron, a beta(3)-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs. 2010;13(10):713–722.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Michel MC, Gravas S. Safety and tolerability of beta3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies. Expert Opin Drug Saf. 2016;15(5):647–657.
   PubMed Web of Science ®Google Scholar
• Nexception. Velicept Therapeutics, Inc. raises $21 million in series B financing. cited 2016 Nov 23. Available from: http://www.nexeption.com/#!2015dec01velicept-raises-21-million/c17dp.
   Google Scholar
• Kissei Pharmaceutical Company Ltd. Preliminary results of Phase II clinical study of KUC-7483. cited 2016 Nov 23. Available from: http://www.kissei.co.jp/e_contents/relation/2010/20100702.html.
   Google Scholar
• Kissei Pharmaceutical Company Ltd. Kissei and Kyorin signed an agreement for co-development and co-marketing of KRP-114V. cited 2016 Nov 23. Available from: https://www.kissei.co.jp/e_contents/l3/l4/Vcms4_00000922.html.
   Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Assessment report: Betmiga. cited 2016 Nov 23. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002388/WC500137308.pdf.
   Google Scholar
• Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4ʹ-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642–647.
   PubMed Web of Science ®Google Scholar
• Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62(6):1165–1173.
   PubMed Web of Science ®Google Scholar
• Aizawa N, Homma Y, Igawa Y. Effects of L-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat. Neurourol Urodyn. 2015;34(4):368–374.
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Ukai M, Watanabe M, et al. Effect of mirabegron, a novel beta3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):71–78.
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Ukai M, Watanabe M, et al. Pharmacological profile of the selective beta3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(11):1001–1008.
   PubMed Web of Science ®Google Scholar
• Granato C, Korstanje C, Guilloteau V, et al. Prostaglandin E2 excitatory effects on rat urinary bladder: a comparison between the beta-adrenoceptor modulation of non-voiding activity in vivo and micro-contractile activity in vitro. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(7):727–735.
   PubMed Web of Science ®Google Scholar
• Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the beta(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110(2 Pt 2):E132–42.
   Web of Science ®Google Scholar
• Sawada N, Nomiya M, Hood B, et al. Protective effect of a beta3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol. 2013;64(4):664–671.
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of the selective beta3-adrenoceptor agonist mirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(3):247–253.
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9(4):433–448.
   PubMed Web of Science ®Google Scholar
• Sadananda P, Drake MJ, Paton JF, et al. A functional analysis of the influence of beta3-adrenoceptors on the rat micturition cycle. J Pharmacol Exp Ther. 2013;347(2):506–515.
   PubMed Web of Science ®Google Scholar
• Eastham J, Stephenson C, Korstanje K, et al. The expression of beta3-adrenoceptor and muscarinic type 3 receptor immuno-reactivity in the major pelvic ganglion of the rat. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(7):695–708.
   PubMed Web of Science ®Google Scholar
• Gillespie JI, Rouget C, Palea S, et al. The characteristics of intrinsic complex micro-contractile activity in isolated strips of the rat bladder. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(7):709–718.
   PubMed Web of Science ®Google Scholar
• Gillespie JI, Rouget C, Palea S, et al. Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(7):719–726.
   PubMed Web of Science ®Google Scholar
• Gillespie JI, Rouget C, Palea S, et al. The actions of prolonged exposure to cholinergic agonists on isolated bladder strips from the rat. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(7):737–747.
   PubMed Web of Science ®Google Scholar
• Alexandre EC, Kiguti LR, Calmasini FB, et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade. Br J Pharmacol. 2016;173(3):415–428.
   PubMed Web of Science ®Google Scholar
• D’Agostino G, Maria condino A, Calvi P. Involvement of beta3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015;758:115–122.
   PubMed Web of Science ®Google Scholar
• Moniotte S, Vaerman JL, Kockx MM, et al. Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol. 2001;33(12):2121–2133.
   PubMed Web of Science ®Google Scholar
• Michel MC, Harding SE, Bond RA. Are there functional beta(3)-adrenoceptors in the human heart? Br J Pharmacol. 2011;162(4):817–822.
   PubMed Web of Science ®Google Scholar
• Iitsuka H, Tokuno T, Amada Y, et al. Pharmacokinetics of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Clin Drug Investig. 2014;34(1):27–35.
   PubMed Web of Science ®Google Scholar
• Iitsuka H, Van Gelderen M, Katashima M, et al. Pharmacokinetics of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects. Clin Ther. 2015;37(5):1031–1044.
   PubMed Web of Science ®Google Scholar
• Lee J, Moy S, Meijer J, et al. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013;33(6):429–440.
   PubMed Web of Science ®Google Scholar
• Krauwinkel W, Dickinson J, Schaddelee M, et al. The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014;39(1):43–52.
   PubMed Web of Science ®Google Scholar
• Kashyap M, Tyagi P. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013;9(5):617–627.
   PubMed Web of Science ®Google Scholar
• Van Gelderen M, Tretter R, Meijer J, et al. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men. Int J Clin Pharmacol Ther. 2014;52(8):693–701.
   PubMed Web of Science ®Google Scholar
• Krauwinkel WJJ, Kerbusch VMM, Meijer J, et al. Evaluation of the pharmacokinetic interaction between the β3-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(3):255–263.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–295.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–320.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–1395.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, Van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–632.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Igawa Y, et al. Efficacy and safety of the selective β3-adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study. Low Urin Tract Symptoms. 2014;7(2):84–92.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–960.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Ikeda Y, Ohkawa S. Phase III study to assess long-term (52-week) safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in Japanese patients with overactive bladder. Low Urin Tract Symptoms. 2015. DOI:10.1111/luts.12107
   Web of Science ®Google Scholar
• Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685–692.
   PubMed Web of Science ®Google Scholar
• Nozawa Y, Kato D, Tabuchi H, et al. Safety and effectiveness of mirabegron in patients with overactive bladder in a real-world clinical setting: a Japanese post-marketing study. Low Urin Tract Symptoms. 2016. DOI:10.111/luts.12148
   Google Scholar
• Matsukawa Y, Takai S, Funahashi Y, et al. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology. 2015;85(4):786–790.
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: epiLUTS. BJU Int. 2009;103(Suppl 3):12–23.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–1327.
   PubMed Web of Science ®Google Scholar
• Otsuki H, Kosaka T, Nakamura K, et al. β3-adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45(1):53–60.
   PubMed Web of Science ®Google Scholar
• Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921–926.
   PubMed Web of Science ®Google Scholar
• Schabert VF, Bavendam T, Goldberg EL, et al. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15(4 Suppl):S118–22.
   PubMedGoogle Scholar
• Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urol. 2013;13:45.
   PubMed Web of Science ®Google Scholar
• Batista JE, Kolbl H, Herschorn S, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7(4):167–179.
   PubMed Web of Science ®Google Scholar
• Macdiarmid SA. Maximizing the treatment of overactive bladder in the elderly. Rev Urol. 2008;10(1):6–13.
   PubMedGoogle Scholar
• Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666–675.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Wein A, Nicholson S, et al. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–1033.
   PubMed Web of Science ®Google Scholar
• Chapple C, Khullar V, Nitti VW, et al. Efficacy of the beta3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. Eur Urol. 2015;67(1):11–14.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Khullar V, Wang JT, et al. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010;106(6):816–821.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Kaplan SA, Sun F, et al. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents? Urology. 2014;83(5):1023–1029.
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–765.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Nitti VW, Khullar V, et al. Onset of action of the beta3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;32(6):1565–1572.
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ Jr., O’Leary MP, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol. 1992;148(5):1549–1557; discussion 64.
   Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997;104(12):1374–1379.
   PubMedGoogle Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563–574.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079–1086.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Patient-reported outcomes with the beta-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourol Urodyn. 2016;35(8):987–994.
   PubMed Web of Science ®Google Scholar
• Castro-Diaz D, Chapple CR, Hakimi Z, et al. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. Qual Life Res. 2015;24(7):1719–1727.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the beta3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Int J Clin Pract. 2014;68(8):972–985.
   PubMed Web of Science ®Google Scholar
• Malik M, Van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Amarenco G, Lopez Aramburu MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32(8):1116–1122.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–1458.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency. Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events. cited 2016 Nov 23. Available from: https://www.gov.uk/drug-safety-update/mirabegron-betmiga-risk-of-severe-hypertension-and-associated-cerebrovascular-and-cardiac-events.
   Google Scholar
• European Medicines Agency. Betmiga® summary of product characteristics. cited 2016 Nov 23. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002388/WC500137309.pdf.
   Google Scholar
• Astellas Pharma US Inc. Myrbetriq^TM full prescribing information. cited 2016 Nov 23. Available from: https://www.us.astellas.com/docs/myrbetriq-full-pi.pdf.
   Google Scholar
• Gericke A, Bohmer T, Michel MC. beta3-adrenoceptors: a drug target in ophthalmology? Naunyn Schmiedebergs Arch Pharmacol. 2013;386(4):265–267.
   PubMed Web of Science ®Google Scholar
• Novack GD, Lewis RA, Vogel R, et al. Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther. 2013;29(7):674–680.
   PubMed Web of Science ®Google Scholar
• Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32(4):621–638.
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–588.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015;116(4):612–622.
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70:136–145.10.1016/j.eururo.2016.02.030.
   PubMed Web of Science ®Google Scholar
• MacDiarmid S, Al-Shukri S, Barkin J, et al. Mirabegron as add-on treatment to solifenacin in incontinent overactive bladder patients with an inadequate response to solifenacin monotherapy: responder analyses and patient-reported outcomes from the BESIDE study. J Urol. 2016;196(3):809–818.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Ivanovskaya M, et al. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Arch Gerontol Geriatr. 2015;61(2):212–216.
   PubMed Web of Science ®Google Scholar
• Nitti V, Rovner ES, Franks B, et al. Persistence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits. 2016;8(2):e25–e33.
   Google Scholar
• Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–350.
   PubMed Web of Science ®Google Scholar
• Europen Medicines Agency. Flomax Relief MR Summary of Prescribing Information. cited 2016 Nov 23. Available from: https://www.medicines.org.uk/emc/medicine/22738/SPC/Flomax+Relief+MR/.
   Google Scholar
• RAD-AR. Harnal D Drug Information Sheet. cited 2016 Nov 23. Available from: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32281.
   Google Scholar
• Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular safety of beta3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311–323.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336.
   PubMed Web of Science ®Google Scholar
• Chiaffarino F, Parazzini F, Lavezzari M, et al. Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol. 2003;43(5):535–538.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study of YM178 in patients with symptomatic overactive bladder (DRAGON). cited 2016 Nov 23. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00337090?term=NCT00337090&rank=1.
   Google Scholar